Research advances toward more effective, long-lasting and side effect-free cancer treatments
The Baylor team is building the case for SRC-3 as a promising therapeutic target for next-generation cancer immunotherapy.
Read More
The Baylor team is building the case for SRC-3 as a promising therapeutic target for next-generation cancer immunotherapy.
Read MoreThe research warrants continuing investigations to translate the findings into a novel, more effective and longer-lasting cancer therapy.
Read MoreThis study has advanced our understanding of the molecular mechanisms underlying the tumor-promoting activity of MAPK4.
Read MoreThe findings in animal models warrant continuing investigations to develop a novel, more effective and longer-lasting cancer therapy.
Read MoreThe researchers took a close look into what drives the growth of advanced tumors that have become resistant to standard castration therapy.
Read MoreThe bone microenvironment prompts changes in breast cancer cells that help them escape treatment and become more invasive.
Read MoreInhibiting MAPK4 simultaneously inactivated both androgen receptor and AKT and stopped cancer growth in animal models.
Read MoreDetailed 3-D studies reveal how the androgen receptor is put together as a functional complex that drives prostate cancer.
Read MoreA fusion gene is a new gene made by joining parts of two different genes. The current thought is that fusion genes can happen in
Read MoreThe five winners of this year’s Michael E. DeBakey M.D. Award for Research Excellence exemplify the breadth and depth of scientific research at Baylor College
Read More